An initial public offering of almost 1.6 million shares has been priced by Sunnyvale, Calif.-based Viveve in hopes of obtaining about $13 million. The company, which makes a device for nonsurgical treatment of postpartum vaginal laxity, has boosted the value of the uplisting after saying last month it hoped to raise $11.5 million in the offering.
Symetis said it is selling about $83 million of company shares in an initial public offering. The Swiss replacement heart valve manufacturer said the IPO, which begins Sept. 29 in Zurich, will help finance its product expansion into the US and Japan.
Immune Design, which specializes in developing immune-based cancer treatments, has filed for an initial public offering with the goal of securing $60 million. The Seattle-based biotech firm will use the money to support clinical trials of its cancer drug candidates.
Mainstay Medical, an Irish firm specializing in orthopedic devices, has filed for an initial public offering in Ireland and Paris in hopes of obtaining about $31.7 million. Meanwhile, U.K. endovascular aneurysm repair device firm Lombard Medical Technologies has canceled its previously announced plans to go public in the U.S.
Mako Surgical Corp. has lowered the price range for its planned initial public offering; originally the company expected its 5.1 million shares to sell for $14 to $16 per share but now it expects $10 to $11, according to a Securities and Exchange Commission filing. The company now foresees $47.1 million from the IPO, down from $68.4 million.